MDS Nordion Provides Update to Medical Isotope Customers
01 Décembre 2007 - 12:44AM
PR Newswire (US)
OTTAWA, Nov. 30 /PRNewswire-FirstCall/ -- MDS Nordion, a leading
provider of medical isotopes and radiopharmaceuticals, has provided
an update to their medical isotope customers about a temporary
supply issue. MDS Nordion has received information from their
primary supplier regarding an interruption in the supply of
molybdenum-99 used in the manufacturing of technetium-99m
generators and iodine-131. The primary supplier has advised MDS
Nordion that a scheduled reactor maintenance shutdown has been
extended to complete an upgrade to the electrical system,
addressing a technical regulatory issue. MDS Nordion's primary
supplier is working closely with their regulator, the Canadian
Nuclear Safety Commission, to finalize and complete implementation
of their upgrade plan. At the same time, MDS Nordion is working
closely with their global supply network to mitigate the impact of
this temporary supply issue on their customers. Based on our
current information, an approval of the upgrade plan is anticipated
shortly with a targeted return to full production in mid-December.
The impact of this interruption is currently expected to reduce
EBITDA by up to approximately US $4 million in the first quarter of
2008. About MDS Nordion MDS Nordion (http://www.mdsnordion.com/) is
a world leader in medical isotopes, radiation and related
technologies. It is a business unit of MDS Inc.
(TSX:MDS)(NYSE:MDZ). MDS Inc. is a global life sciences company
that provides market-leading products and services for the
development of drugs and diagnosis and treatment of disease. We are
a leading global provider of pharmaceutical contract research,
medical isotopes for molecular imaging, radiotherapeutics, and
analytical instruments. MDS Inc. has more than 6,200 highly skilled
people in 28 countries. Find out more at http://www.mdsinc.com/ or
by calling 1-888-MDS-7222, 24 hours a day. Forward-Looking
Statement This document contains forward-looking statements. Some
forward-looking statements may be identified by words like
"expects", "anticipates", "plans", "intends", "indicates",
"targeted" or similar expressions. The statements are not a
guarantee of future impact or performance and are inherently
subject to risks and uncertainties. The actual impact to the
Company of the maintenance shutdown could differ materially from
that currently anticipated due to a number of factors, including,
the actual timing of a return to full production and other risk
factors identified in other documents filed by the Company with
Canadian and US securities regulatory authorities from time to
time. DATASOURCE: MDS Nordion CONTACT: Media: Shelley Maclean,
Manager External Communications, MDS Nordion, (613) 592-3400 ext.
2414, ; Investors: Sharon Mathers, Senior Vice-President, Investor
Relations and External Communications, MDS Inc., (416) 675-6777 x
34721,
Copyright
Mds (NYSE:MDZ)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Mds (NYSE:MDZ)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Mds (New York Stock Exchange): 0 recent articles
Plus d'articles sur Mds